Showing results (111-120 of 158) with videos related to
Sort By:
Pageof 16
American Journal of Respiratory and Critical Care Medicine|November 25, 2003
Sitaxsentan therapy for pulmonary arterial hypertensionRobyn J Barst, David Langleben, Adaani Frost, et al.American Heart Journal|December 26, 2025
Large-bore mechanical thrombectomy vs standard of care for acute high-risk pulmonary embolism: rationale and design of the PERSEVERE randomized controlled trialRomain Chopard, Lukas Hobohm, Stefano Barco, et al.American Heart Journal|January 21, 2014
Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized studyKelly M Chin, David B Badesch, Ivan M Robbins, et al.The European Respiratory Journal|August 19, 2017
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertensionSean Gaine, Kelly Chin, Gerry Coghlan, et al.Circulation|April 16, 2019
Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial HypertensionKelly M Chin, Lewis J Rubin, Richard Channick, et al.Journal of the American College of Cardiology|June 27, 2009
End points and clinical trial design in pulmonary arterial hypertensionVallerie V McLaughlin, David B Badesch, Marion Delcroix, et al.BMJ Open Respiratory Research|March 22, 2024
Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE studyJason Weatherald, Steven D Nathan, Karim El-Kersh, et al.Journal of Thrombosis and Haemostasis : JTH|May 13, 2023
Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b studyThomas Vanassche, Rachel P Rosovsky, Fares Moustafa, et al.American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 8, 2018
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON StudyJ Gerry Coghlan, Richard Channick, Kelly Chin, et al.Ebiomedicine|December 13, 2023
The ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cellsMichael I Lewis, Shelley Shapiro, Ronald J Oudiz, et al.Pageof 16